Scarica l'app Stockscreener
4.9593
1.39%
-0.0707
Precedente Chiudi:
$5.03
Aprire:
$5.01
Volume 24 ore:
45,113
Relative Volume:
0.05
Capitalizzazione di mercato:
$273.56M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-2.9345
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
+4.42%
1M Prestazione:
-11.43%
6M Prestazione:
-44.08%
1 anno Prestazione:
-15.79%
Intervallo 1D:
$4.92
$5.0526
Intervallo di 1 settimana:
$4.48
$5.1693
Portata 52W:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.94 | 273.56M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.68 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.97 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.04 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.23 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.67 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics Elects New Directors at Annual Meeting - TipRanks
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Purchased by Squarepoint Ops LLC - Defense World
Candel Therapeutics appoints new board member ahead of BLA submission By Investing.com - Investing.com South Africa
Small cap wrap: HIVE Digital, TNR Gold, Candel Therapeutics... - Proactive financial news
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., To Board - citybiz
Candel Therapeutics, Inc. Appoints Maha Radhakrishnan to Its Board of Directors - marketscreener.com
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board - Proactive financial news
Candel Therapeutics appoints new board member ahead of BLA submission - Investing.com
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Former Biogen Chief Medical Officer Joins Candel Board as Prostate Cancer Drug Nears FDA Filing - Stock Titan
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Bought by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Takes Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - MSN
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL St - GuruFocus
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com
Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga
Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com Australia
Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times
Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan
Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times
Candel Therapeutics to Host Investor Conference Call - GlobeNewswire
Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN
Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World
Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel’s phase 3 trial for prostate cancer therapy shows promise By Investing.com - Investing.com Nigeria
Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Candel Therapeutics Inc Azioni (CADL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Mar 18 '25 |
Sale |
8.76 |
45,316 |
396,995 |
52,493 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Option Exercise |
1.55 |
18,000 |
27,900 |
128,673 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Sale |
8.76 |
32,146 |
281,673 |
96,527 |
| Tak Paul Peter | Chief Executive Officer |
Mar 18 '25 |
Sale |
8.77 |
25,772 |
226,023 |
226,140 |
| Tak Paul Peter | Chief Executive Officer |
Mar 19 '25 |
Sale |
9.00 |
400 |
3,601 |
225,740 |
| Tyagarajan Seshu | Chief Technology Officer |
Mar 17 '25 |
Sale |
8.82 |
31,278 |
275,947 |
85,512 |
| Schoch Charles | See Remarks |
Mar 17 '25 |
Sale |
8.83 |
5,000 |
44,169 |
38,038 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):